J Stroke.  2025 May;27(2):161-168. 10.5853/jos.2024.04623.

The Association of Lipoprotein(a) and Stroke Recurrence: A Systematic Review and Meta-Analysis

Affiliations
  • 1Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
  • 2Department of Neurology & Stroke, Eberhard-Karls University of Tübingen, Tübingen, Germany
  • 3Hertie Institute for Clinical Brain Research, Eberhard-Karls University of Tübingen, Tübingen, Germany
  • 4Research Unit and Diabetes Center, Second Department of Internal Medicine, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
  • 5Stroke Center, Lisbon Central University Hospital – ULS São José, and Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
  • 6Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Via Vetoio, Italy
  • 7Department of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland
  • 8Third Department of Cardiology, Sotiria Thoracic Diseases General Hospital, National and Kapodistrian University of Athens, Athens, Greece

Abstract

Background and Purpose
Lipoprotein(a) [Lp(a)] is a lipoprotein structurally similar to low-density lipoprotein and is considered a genetically determined risk factor for cardiovascular disease. Although Lp(a) has been linked to ischemic stroke, its role in secondary stroke prevention, particularly in stroke recurrence, remains unclear.
Methods
A systematic search of MEDLINE and Scopus databases was conducted to identify randomized controlled trials (RCTs) and observational studies reporting Lp(a) levels in patients with ischemic stroke or transient ischemic attack. The primary outcome was stroke recurrence, and secondary outcomes included poor functional outcome, all-cause mortality, and recurrent vascular events. Pooled odds ratios (ORs) were calculated using a random-effects model.
Results
A total of 12 studies, including one RCT post hoc analysis and 11 observational studies, comprising 17,903 patients (mean age 63 years, 38% female), were included. Elevated Lp(a) levels were significantly associated with increased stroke recurrence (OR: 1.69; 95% confidence interval [CI]: 1.09–2.63; P=0.020) and poor functional outcome (OR: 2.09; 95% CI: 1.40–3.11; P<0.001). No significant associations were found between Lp(a) levels and all-cause mortality (OR: 2.20; 95% CI: 0.89–5.43; P=0.088) or recurrent vascular events (OR: 2.66; 95% CI: 0.95–7.44; P=0.063).
Conclusion
Elevated Lp(a) levels are linked to increased stroke recurrence and poor functional outcome in stroke patients. Lp(a) may represent a novel therapeutic target in secondary stroke prevention in addition to a promising biomarker.

Keyword

Lipoprotein(a); Ischemic stroke; Stroke recurrence; Functional outcome; Mortality; Systematic review; Meta-analysis
Full Text Links
  • JOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2025 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr